Neuroendocrinological treatment targets for posttraumatic stress disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Seoyoung | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.date.accessioned | 2021-09-01T17:52:26Z | - |
dc.date.available | 2021-09-01T17:52:26Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-03-02 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/67021 | - |
dc.description.abstract | Posttraumatic stress disorder ( PTSD) is prevalent, disabling, and frequently becomes chronic. Despite this, only two selective serotonergic reuptake inhibitors have been approved to date for its treatment by the United States Food and Drug Administration, and treatment results are often disappointing, with a remission rate of < 30%. Certain neuroendocrinological systems are currently gaining attention with respect to their use for PTSD prevention and treatment as standalone options or medication-enhanced psychotherapy due to their involvement in physiological stress reactions, memory consolidation and extinction, cognitive appraisal to stress, and attachment and resilient coping strategies, which are important in the pathogenesis of PTSD. The hypothalamic-pituitary-adrenal axis system takes the most important role in stress reactions. Hydrocortisone has been studied for the prevention of PTSD, and some meta-analyses have suggested its possible efficacy; furthermore, it has been considered both as monotherapy and as an augmentation to psychotherapy in PTSD patients, with some positive results. Glucocorticoid receptor antagonists and corticotropin-releasing factor type 1 antagonists have also been considered for clinical use in PTSD treatment. Additionally, other neuroendocrinological systems have been studied in PTSD including the use of oxytocin for PTSD prevention and augmentation to psychotherapy, allopregnanolone, and neuropeptide Y (NPY) for PTSD treatment. For now, however, these studies offer only limited evidence of efficacy, thus it is prudent to study this issue more vigorously. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | PITUITARY-ADRENAL AXIS | - |
dc.subject | PLASMA NEUROPEPTIDE-Y | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | PROTEIN 18 KDA | - |
dc.subject | INTRANASAL OXYTOCIN | - |
dc.subject | CEREBROSPINAL-FLUID | - |
dc.subject | EMOTIONAL FACES | - |
dc.subject | CARDIAC-SURGERY | - |
dc.subject | COMBAT VETERANS | - |
dc.title | Neuroendocrinological treatment targets for posttraumatic stress disorder | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.1016/j.pnpbp.2018.11.021 | - |
dc.identifier.scopusid | 2-s2.0-85058080703 | - |
dc.identifier.wosid | 000454536600023 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.90, pp.212 - 222 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 90 | - |
dc.citation.startPage | 212 | - |
dc.citation.endPage | 222 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | PITUITARY-ADRENAL AXIS | - |
dc.subject.keywordPlus | PLASMA NEUROPEPTIDE-Y | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | PROTEIN 18 KDA | - |
dc.subject.keywordPlus | INTRANASAL OXYTOCIN | - |
dc.subject.keywordPlus | CEREBROSPINAL-FLUID | - |
dc.subject.keywordPlus | EMOTIONAL FACES | - |
dc.subject.keywordPlus | CARDIAC-SURGERY | - |
dc.subject.keywordPlus | COMBAT VETERANS | - |
dc.subject.keywordAuthor | Posttraumatic stress disorder | - |
dc.subject.keywordAuthor | Treatment | - |
dc.subject.keywordAuthor | Prevention | - |
dc.subject.keywordAuthor | Hydrocortisone | - |
dc.subject.keywordAuthor | Allopregnanolone | - |
dc.subject.keywordAuthor | Oxytocin | - |
dc.subject.keywordAuthor | Neuropeptide Y | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.